GAMMA Investing LLC Increases Stake in Dynavax Technologies Corporation (NASDAQ:DVAX)

GAMMA Investing LLC grew its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 88.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,729 shares of the biopharmaceutical company’s stock after buying an additional 3,627 shares during the period. GAMMA Investing LLC’s holdings in Dynavax Technologies were worth $100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Schonfeld Strategic Advisors LLC grew its holdings in shares of Dynavax Technologies by 97.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company’s stock valued at $3,964,000 after purchasing an additional 153,302 shares in the last quarter. First Trust Advisors LP purchased a new position in Dynavax Technologies during the fourth quarter worth $847,000. Deep Track Capital LP boosted its stake in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after buying an additional 5,265,000 shares during the period. Deutsche Bank AG boosted its stake in Dynavax Technologies by 49.3% during the fourth quarter. Deutsche Bank AG now owns 126,398 shares of the biopharmaceutical company’s stock worth $1,614,000 after buying an additional 41,720 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Dynavax Technologies by 20.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 2,796 shares during the period. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 6th. JMP Securities decreased their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group decreased their price objective on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $24.00.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $10.28 on Monday. The company has a quick ratio of 10.84, a current ratio of 11.93 and a debt-to-equity ratio of 0.49. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63. The business’s 50 day moving average price is $10.14 and its 200 day moving average price is $11.86. The firm has a market cap of $1.23 billion, a P/E ratio of -19.77 and a beta of 1.03.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The company had revenue of $68.16 million during the quarter, compared to analysts’ expectations of $70.01 million. On average, sell-side analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.